Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Pheniramine→

Pheniramine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
86-21-5
Molecular formula
C16H20N2
Molecular weight
240.3434 g/mol
Drug class
First-generation H1 histamine-receptor antagonistantihistamine
Mechanism of action
Competes with histamine at peripheral H1 receptors and acts as an inverse agonist, reducing histamine-mediated itching, vasodilation, capillary permeability and allergic symptoms. Central H1 antagonism may produce sedation.
Indications / reported uses
  • Relief of symptoms of allergic rhinitis and hay fever.
  • Relief of pruritus and allergic dermatoses; formulation and product authorisation determine approved uses.

Sources: https://www.ncbi.nlm.nih.gov/mesh/68010632 · https://pubchem.ncbi.nlm.nih.gov/compound/4761 · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Pheniramine Environmental Risk Assessment (ERA) (the Pheniramine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.